ArticleApplied and environmental microbiology2007
Novel whole-cell antibiotic biosensors for compound discovery.
Article in Applied and environmental microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 128 citations in OpenAlex.
- Broad-Spectrum, Cell Envelope-Active Marinocyclin Antibiotics From a Coral-Derived Bacterium Are Effective Against Colistin-Resistant Bacteria.Angewandte Chemie (International ed. in English) · 2026Article
- Construction of a novel reporter strain indicating inhibition of cell wall biosynthesis.Applied microbiology and biotechnology · 2026Article
- A double-layer plate method for rapid screening of cell wall-targeting antibiotic producers using a microbial whole-cell biosensor.Applied and environmental microbiology · 2026Article
- Translating biosynthetic gene cluster architecture into biosensor design for microbial natural product discovery.Essays in biochemistry · 2026Review
- Synergistic mode of action of a ceftazidime-hexa-arginine conjugate with resistance-overcoming properties.Microbiology spectrum · 2026Article
- Proteotoxic Stress Bioreporter Enables Mechanism-Informed Antibiotic Discovery.Journal of natural products · 2026Article
- Multiplexing antibiotic screening assay in droplet microfluidics.Scientific reports · 2026Article
- The Spermidine Synthase Gene as a Reporter of Transcription Inhibition inInternational journal of molecular sciences · 2026Article
- Discovery of Coerumycin, a Cinnamycin-like Lantibiotic fromAntibiotics (Basel, Switzerland) · 2026Article
- High-Frequency Microfluidic Fractionation for Compound-Resolved Bioactivity-Based Metabolomics.Analytical chemistry · 2025Article
- The expression of different gene constructs in Escherichia coli SM lux biosensor after exposure to drugs.Scientific reports · 2024Article
- Article
- Article
- Improved production of RNA-inhibiting antimicrobial peptide by Bacillus licheniformis MCC 2514 facilitated by a genetic algorithm optimized medium.Bioprocess and biosystems engineering · 2024Article
- A Staphylococcus capitis strain with unusual bacteriocin production.Microbial biotechnology · 2023Article
- What the Hel: recent advances in understanding rifampicin resistance in bacteria.FEMS microbiology reviews · 2023Article
- High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery.Metabolites · 2023Review
- An extensively validated whole-cell biosensor for specific, sensitive and high-throughput detection of antibacterial inhibitors targeting cell-wall biosynthesis.The Journal of antimicrobial chemotherapy · 2023Article
- Antibiotic Susceptibility Testing with Raman Biosensing.Antibiotics (Basel, Switzerland) · 2022Review
- Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes.Microbiology spectrum · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cells containing reporters which are specifically induced via selected promoters are used in pharmaceutical drug discovery and in environmental biology. They are used in screening for novel drug candidates and in the detection of bioactive compounds in environmental samples. In this study, we generated and validated a set of five Bacillus subtilis promoters fused to the firefly luciferase reporter gene suitable for cell-based screening, enabling the as yet most-comprehensive high-throughput diagnosis of antibiotic interference in the major biosynthetic pathways of bacteria: the biosynthesis of DNA by the yorB promoter, of RNA by the yvgS promoter, of proteins by the yheI promoter, of the cell wall by the ypuA promoter, and of fatty acids by the fabHB promoter. The reporter cells mainly represent novel antibiotic biosensors compatible with high-throughput screening. We validated the strains by developing screens with a set of 14,000 pure natural products, representing a source of highly diverse chemical entities, many of them with antibiotic activity (6% with anti-Bacillus subtilis activity of </=25 mug/ml]). Our screening approach is exemplified by the discovery of classical and novel DNA synthesis and translation inhibitors. For instance, we show that the mechanistically underexplored antibiotic ferrimycin A1 selectively inhibits protein biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.